Ashland Q4 adjusted profit misses estimates; forecasts higher 2027 sales
Ashland Q4 adjusted profit misses estimates; forecasts higher 2027 sales
Overview
U.S. specialty ingredients maker's fiscal Q4 revenue rose 4% but slightly missed analyst expectations
Adjusted EPS for Q4 missed analyst expectations despite rising to $1.12 from $1.08 a year earlier
Company posted a net loss of $16 mln, versus net income a year earlier
Outlook
Ashland sees fiscal 2027 sales of $1.905-$1.975 bln
Company expects fiscal 2027 adjusted EBITDA of $405-$435 mln
Ashland expects resilient demand in Life Sciences and Personal Care for fiscal 2027
Result Drivers
HIGHER SALES VOLUMES - Co said Q4 sales volumes increased, driven by Life Sciences and Personal Care growth
PRICE INCREASES - Co said pricing actions offset higher raw material costs in Q4
SPECIALTY ADDITIVES PRESSURE - Co said lower Hopewell productivity and unfavorable absorption reduced Specialty Additives earnings
Company press release: ID:nGNX7yHWJn
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Slight Miss* | $498 mln | $501.81 mln (8 Analysts) |
Q4 Loss Per Share |
| $0.35 |
|
Q4 Net Loss |
| $16 mln |
|
Q4 Adjusted EPS | Miss | $1.12 | $1.28 (10 Analysts) |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the diversified chemicals peer group is "buy"
Wall Street's median 12-month price target for Ashland Inc. is $80.00, about 9.6% above its November 3 closing price of $73.02
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 17 three months ago
Reuters Recommended Reads
Nov 3 - DuPont raises annual profit forecasts, sees upbeat Q4 on healthcare, aerospace strength
Nov 2 - Celanese Q3 sales rise 6%
Nov 3 - Flavors and fragrances maker IFF's Q3 sales beat; low end of 2026 outlook raised
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Ashland
See all newsEvonik remains opposed to takeover offer after meeting BASF, says source familiar with the matter
Evonik still against takeover by BASF after talks, Handelsblatt reports
Evonik remains opposed to BASF bid after meeting, says person familiar with the matter (updated)
BASF, Evonik management held talks over weekend, says person familiar with matter
US RESEARCH ROUNDUP-Cencora, Dave, Uber